<scp>MicroRNA</scp> in skeletal muscle development, growth, atrophy, and disease

Kovanda, Anja; Režen, Tadeja; Rogelj, Boris

doi:10.1002/wrna.1227

Cited by 55 publications

(43 citation statements)

References 166 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these appear to exert conserved roles across species and have functions from the early phases of myogenesis, from stem cell differentiation through to myofiber atrophy. Within these a subset commonly identified as myomiRs are highly expressed within skeletal muscle (Kovanda et al, 2014) and have reported roles in skeletal muscle maintenance processes (McCarthy, 2014a). We have identified a number of differences in miR expression between powerlifters and controls which through transcriptional regulation (Figure 6) may partially explain the divergent powerlifter phenotype.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs in Muscle: Characterizing the Powerlifter Phenotype

et al. 2017

View full text Add to dashboard Cite

Powerlifters are the epitome of muscular adaptation and are able to generate extreme forces. The molecular mechanisms underpinning the significant capacity for force generation and hypertrophy are not fully elucidated. MicroRNAs (miRs) are short non-coding RNA sequences that control gene expression via promotion of transcript breakdown and/or translational inhibition. Differences in basal miR expression may partially account for phenotypic differences in muscle mass and function between powerlifters and untrained age-matched controls. Muscle biopsies were obtained from m. vastus lateralis of 15 national level powerlifters (25.1 ± 5.8 years) and 13 untrained controls (24.1 ± 2.0 years). The powerlifters were stronger than the controls (isokinetic knee extension at 60°/s: 307.8 ± 51.6 Nm vs. 211.9 ± 41.9 Nm, respectively P < 0.001), and also had larger muscle fibers (type I CSA 9,122 ± 1,238 vs. 4,511 ± 798 μm2 p < 0.001 and type II CSA 11,100 ± 1,656 vs. 5,468 ± 1,477 μm2 p < 0.001). Of the 17 miRs species analyzed, 12 were differently expressed (p < 0.05) between groups with 7 being more abundant in powerlifters and five having lower expression. Established transcriptionally regulated miR downstream gene targets involved in muscle mass regulation, including myostatin and MyoD, were also differentially expressed between groups. Correlation analysis demonstrates the abundance of eight miRs was correlated to phenotype including peak strength, fiber size, satellite cell abundance, and fiber type regardless of grouping. The unique miR expression profiles between groups allow for categorization of individuals as either powerlifter or healthy controls based on a five miR signature (miR-126, -23b, -16, -23a, -15a) with considerable accuracy (100%). Thus, this unique miR expression may be important to the characterization of the powerlifter phenotype.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNAs in Muscle: Characterizing the Powerlifter Phenotype

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Here we will review miRNAs involved in glucose homeostasis and lipid metabolism in skeletal muscle, with an emphasis on metabolic disorders such as type 2 diabetes and the adaptive response to exercise training. Additionally we will raise some methodological considerations for studying miRNAs, as well as challenges investigators may A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 4 face when elucidating the direct role of miRNAs in the regulation of glucose and lipid metabolism in skeletal muscle.…”

Section: Introductionmentioning

confidence: 99%

“…Several lines of evidence suggest an important role for microRNAs (miRNAs) in skeletal muscle development and hypertrophy (for review see [4]), however, much less is known regarding miRNA regulation of glucose and lipid metabolism in skeletal muscle. In this respect, miRNAs may fine tune the expression of networks of genes that control glucose and lipid metabolism in health and disease.…”

Section: Introductionmentioning

confidence: 99%

microManaging glucose and lipid metabolism in skeletal muscle: Role of microRNAs

Massart

Katayama

Krook

2016

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biolog

View full text Add to dashboard Cite

“…MicroRNAs are genetically conserved small non‐coding RNAs, containing about 22 nucleotides that post‐transcriptionally control gene expression. Skeletal muscle‐enriched microRNAs (myomiRs) play an important role in the regulation of muscle development, growth, regeneration, and metabolism . The microRNA‐1 and microRNA‐133a can regulate myogenesis by suppressing the predicted target gene histone deacetylase 4 (HDAC4), which upregulates myogenic markers as myocyte enhancer factor 2C (MEF2c), myogenic differentiation factor D (MyoD), and follistatin expression .…”

Section: Introductionmentioning

confidence: 99%

Effects of aerobic and inspiratory training on skeletal muscle microRNA‐1 and downstream‐associated pathways in patients with heart failure

Antunes‐Correa

Trevizan

Bacurau

et al. 2019

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background The exercise intolerance in chronic heart failure with reduced ejection fraction (HFrEF) is mostly attributed to alterations in skeletal muscle. However, the mechanisms underlying the skeletal myopathy in patients with HFrEF are not completely understood. We hypothesized that (i) aerobic exercise training (AET) and inspiratory muscle training (IMT) would change skeletal muscle microRNA‐1 expression and downstream‐associated pathways in patients with HFrEF and (ii) AET and IMT would increase leg blood flow (LBF), functional capacity, and quality of life in these patients. Methods Patients age 35 to 70 years, left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association functional classes II–III, were randomized into control, IMT, and AET groups. Skeletal muscle changes were examined by vastus lateralis biopsy. LBF was measured by venous occlusion plethysmography, functional capacity by cardiopulmonary exercise test, and quality of life by Minnesota Living with Heart Failure Questionnaire. All patients were evaluated at baseline and after 4 months. Results Thirty‐three patients finished the study protocol: control (n = 10; LVEF = 25 ± 1%; six males), IMT (n = 11; LVEF = 31 ± 2%; three males), and AET (n = 12; LVEF = 26 ± 2%; seven males). AET, but not IMT, increased the expression of microRNA‐1 (P = 0.02; percent changes = 53 ± 17%), decreased the expression of PTEN (P = 0.003; percent changes = −15 ± 0.03%), and tended to increase the p‐AKTser473/AKT ratio (P = 0.06). In addition, AET decreased HDAC4 expression (P = 0.03; percent changes = −40 ± 19%) and upregulated follistatin (P = 0.01; percent changes = 174 ± 58%), MEF2C (P = 0.05; percent changes = 34 ± 15%), and MyoD expression (P = 0.05; percent changes = 47 ± 18%). AET also increased muscle cross‐sectional area (P = 0.01). AET and IMT increased LBF, functional capacity, and quality of life. Further analyses showed a significant correlation between percent changes in microRNA‐1 and percent changes in follistatin mRNA (P = 0.001, rho = 0.58) and between percent changes in follistatin mRNA and percent changes in peak VO2 (P = 0.004, rho = 0.51). Conclusions AET upregulates microRNA‐1 levels and decreases the protein expression of PTEN, which reduces the inhibitory action on the PI3K‐AKT pathway that regulates the skeletal muscle tropism. The increased levels of microRNA‐1 also decreased HDAC4 and increased MEF2c, MyoD, and follistatin expression, improving skeletal muscle regeneration. These changes associated with the increase in muscle cross‐sectional area and LBF contribute to the attenuation in skeletal myopathy, and the improvement in functional capacity and quality of life in patients with HFrEF. IMT caused no changes in microRNA‐1 and in the downstream‐associated pathway. The increased functional capacity provoked by IMT seems to be associated with amelioration in the respiratory function instead of changes in skeletal muscle. http://ClinicalTrials.gov (Identifier: NCT01747395)

show abstract

MicroRNA in skeletal muscle development, growth, atrophy, and disease

Cited by 55 publications

References 166 publications

MicroRNAs in Muscle: Characterizing the Powerlifter Phenotype

MicroRNAs in Muscle: Characterizing the Powerlifter Phenotype

microManaging glucose and lipid metabolism in skeletal muscle: Role of microRNAs

Effects of aerobic and inspiratory training on skeletal muscle microRNA‐1 and downstream‐associated pathways in patients with heart failure

Contact Info

Product

Resources

About